National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK; Translational Health Sciences, Bristol Medical School, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Bristol, UK; Central Finland Health Care District Hospital District, Department of Medicine, Finland District, Jyväskylä, Finland; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK.
Central Finland Health Care District Hospital District, Department of Medicine, Finland District, Jyväskylä, Finland; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio, Finland.
Respir Med. 2022 Aug;199:106894. doi: 10.1016/j.rmed.2022.106894. Epub 2022 May 29.
Circulating C-reactive protein (CRP) and albumin are known biomarkers of systemic inflammation. C-reactive protein-to-albumin ratio (CAR), a novel biomarker, has been suggested to be a more reliable risk indicator for inflammatory conditions compared to CRP or albumin alone. Inflammatory processes underlie the pathophysiology of pneumonia, but the association between CAR and pneumonia has not been previously investigated. We aimed to assess the prospective association of CAR with pneumonia risk.
C-reactive protein and albumin were measured in serum samples at baseline from 2489 men aged 42-61 years, from the Kuopio Ischemic Heart Disease study. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated from Cox regression analysis.
During a median follow-up of 26.1 years, 598 cases of pneumonia were recorded. In analysis adjusted for age, body mass index, smoking status, history of type 2 diabetes, prevalent coronary heart disease, history of asthma, history of chronic bronchitis, history of tuberculosis, alcohol consumption, socioeconomic status, leisure-time physical activity, and total energy intake, the HR (95% CI) for pneumonia comparing top versus bottom thirds of CAR was 1.62 (1.31-2.00). The corresponding adjusted risk for serum CRP was 1.67 (1.34-2.07). There was no evidence of an association between serum albumin and pneumonia risk.
In middle-aged and older Finnish men, elevated serum CAR and CRP levels were each associated with an increased risk of pneumonia. Further research is needed to replicate these findings in other populations and assess the potential value of CAR in the prevention and management of pneumonia.
已知循环 C 反应蛋白(CRP)和白蛋白是全身炎症的生物标志物。C 反应蛋白与白蛋白比值(CAR)作为一种新型生物标志物,与 CRP 或白蛋白单独相比,其被认为是炎症状态更可靠的风险指标。肺炎的病理生理学基础是炎症过程,但 CAR 与肺炎之间的关联尚未得到研究。我们旨在评估 CAR 与肺炎风险的前瞻性关联。
在库奥皮奥缺血性心脏病研究中,对 2489 名年龄在 42-61 岁的男性进行了基线时血清样本中 CRP 和白蛋白的测量。使用 Cox 回归分析估计危险比(HR)及其 95%置信区间(CI)。
在中位数为 26.1 年的随访期间,记录了 598 例肺炎病例。在调整年龄、体重指数、吸烟状况、2 型糖尿病史、现患冠心病、哮喘史、慢性支气管炎史、结核病史、饮酒、社会经济状况、休闲时间体力活动和总能量摄入后,比较 CAR 最高和最低三分位的肺炎 HR(95%CI)为 1.62(1.31-2.00)。相应调整后的血清 CRP 风险为 1.67(1.34-2.07)。血清白蛋白与肺炎风险之间没有关联的证据。
在中年和老年芬兰男性中,升高的血清 CAR 和 CRP 水平均与肺炎风险增加相关。需要在其他人群中复制这些发现,并评估 CAR 在肺炎预防和管理中的潜在价值。